Literature DB >> 26500994

Impact of Adjuvant Therapy on Survival in Curatively Resected Gallbladder Carcinoma.

Sunil Choudhary1, Anupam Kumar Asthana2.   

Abstract

BACKGROUND: Gallbladder carcinoma (GBC) has the propensity to fail at loco-regional (LR) and distant sites despite aggressive radical surgery. Adjuvant therapy in the form of radiotherapy (RT), systemic chemotherapy (CT) and chemoradiation (CRT) is the usual practice. Due to rarity of this disease, there is limited evidence to suggest the type of adjuvant treatment which should be offered to the patients. AIM: The study was conducted to evaluate the impact of adjuvant treatment on curatively resected GBC patients. SETTINGS AND
DESIGN: Histological proven patients of GBC registered between June, 2008 and July, 2014 were identified from our hospital database and retrospective analysis was done.
MATERIALS AND METHODS: Patients of GBC who had curative resection followed by adjuvant treatment as RT alone, CT alone or CRT were included in the study. STATISTICAL ANALYSIS: Adverse prognostic factors and the effect of adjuvant treatment on overall survival (OS) and disease free survival (DFS) were evaluated using Cox Regression Method and Kaplan Meier plot.
RESULTS: We identified 33 patients of which 23 were Stage I or II disease (Early disease) and the remaining 10 were Stage III or IV disease (Advanced disease). All except one patient had adenocarcinoma. A total of 5 patients were treated with RT alone while 16 patients received CT alone. The remaining 12 patients were treated with CRT. Median follow-up period was 8.5 months. At analysis 4 were alive while the remaining 29 were dead due to disease. With regard to "Early disease" patients who had RT alone, CT alone and CRT, the median OS was 22.3, 10.3 and 15.2 months respectively (p = .440). Cohort of patients with "Advanced disease" who were treated with CT alone and CRT the median OS was 7.5 and 7.0 months respectively (p = .643). On multivariate analysis none of the prognostic factors had an adverse impact on survival.
CONCLUSION: The impact of adjuvant treatment in the form of RT, CT or CRT after curative resection in GBC patients was seen in terms of improved survival but was not statistically significant.

Entities:  

Keywords:  Chemoradiation; Chemotherapy; Gallbladder cancer; Radiotherapy

Year:  2015        PMID: 26500994      PMCID: PMC4606323          DOI: 10.7860/JCDR/2015/15113.6436

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

1.  Outcome of radical surgery for carcinoma of the gallbladder according to the TNM stage.

Authors:  K Tsukada; K Hatakeyama; I Kurosaki; K Uchida; Y Shirai; T Muto; K Yoshida
Journal:  Surgery       Date:  1996-11       Impact factor: 3.982

2.  Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma.

Authors:  Woo Seok Kim; Dong Wook Choi; Dong Do You; Chuan Yu Ho; Jin Seok Heo; Seong Ho Choi
Journal:  J Gastrointest Surg       Date:  2010-01-22       Impact factor: 3.452

3.  Do complications related to laparoscopic cholecystectomy influence the prognosis of gallbladder cancer?

Authors:  C Wullstein; G Woeste; S Barkhausen; E Gross; U T Hopt
Journal:  Surg Endosc       Date:  2002-02-08       Impact factor: 4.584

4.  Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.

Authors:  John J Kresl; Steven E Schild; George T Henning; Leonard L Gunderson; John Donohue; Henry Pitot; Michael G Haddock; David Nagorney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

Review 5.  Long-term results after resection for gallbladder cancer. Implications for staging and management.

Authors:  D L Bartlett; Y Fong; J G Fortner; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

6.  Lymph node spread from carcinoma of the gallbladder.

Authors:  K Tsukada; I Kurosaki; K Uchida; Y Shirai; Y Oohashi; N Yokoyama; H Watanabe; K Hatakeyama
Journal:  Cancer       Date:  1997-08-15       Impact factor: 6.860

7.  Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.

Authors:  Douglas G Gold; Robert C Miller; Michael G Haddock; Leonard L Gunderson; Fernando Quevedo; John H Donohue; Sumita Bhatia; David M Nagorney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-16       Impact factor: 7.038

8.  Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis.

Authors:  Omar Hyder; Rebecca M Dodson; Teviah Sachs; Matthew Weiss; Skye C Mayo; Michael A Choti; Christopher L Wolfgang; Joseph M Herman; Timothy M Pawlik
Journal:  Surgery       Date:  2013-07-19       Impact factor: 3.982

9.  Adjuvant chemoradiation for resected gallbladder cancer: Treatment strategies for one of the leading causes of cancer death in Chilean women.

Authors:  Bettina Müller; José A Sola; Marcela Carcamo; Ana M Ciudad; Cristian Trujillo; Berta Cerda
Journal:  Indian J Cancer       Date:  2013 Jul-Sep       Impact factor: 1.224

10.  Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates.

Authors:  D E Henson; J Albores-Saavedra; D Corle
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

View more
  4 in total

1.  Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis.

Authors:  Yuhree Kim; Neda Amini; Ana Wilson; Georgios A Margonis; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Kenneth Cardona; Shishir K Maithel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2016-05-11       Impact factor: 5.344

2.  Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium.

Authors:  Georgios Antonios Margonis; Faiz Gani; Stefan Buettner; Neda Amini; Kazunari Sasaki; Nikolaos Andreatos; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-08-13       Impact factor: 3.647

3.  Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer.

Authors:  Abhay K Kattepur; Shraddha Patkar; Mahesh Goel; Anant Ramaswamy; Vikas Ostwal
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

4.  Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection.

Authors:  Cheng Chen; Wenming Feng; Yinyuan Zheng; Ying Bao; Min Feng
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.